abstract |
Compounds that form a covalent bond with Bruton's tyrosine kinase (BTK) are disclosed herein. Methods of preparing such compounds are disclosed. Pharmaceutical compositions comprising such compounds are also disclosed. A method of using a BTK inhibitor alone or in combination with other therapeutic agents for treating an autoimmune disease or condition, a xenogenic immune disease or condition, cancer (including lymphoma), and an inflammatory disease or condition is disclosed. |